ArticleThe Journal of biological chemistry2022
Dual Cre and Dre recombinases mediate synchronized lineage tracing and cell subset ablation in vivo.
Article in The Journal of biological chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- LGR5-positive fibroblasts orchestrate skin mechanoadaptation through JAK1 modulation.Nature communications · 2026Article
- Article
- PW1Stem cell research & therapy · 2026Article
- p16Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ureteric stromal progenitors give rise to kidney inner cortical pericytes via an arterial mural cell intermediate.Developmental biology · 2026Article
- Efficient site-specific recombination by self-activating split-Dre recombinase in mammalian cells and E. coli.Journal of biological engineering · 2025Article
- Modeling tumor relapse using proliferation tracing and ablation transgenic mouse.NPJ breast cancer · 2025Article
- Dual genetic tracing demonstrates the heterogeneous differentiation and function of neuromesodermal progenitors in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Multistep allelic conversion in mouse pre-implantation embryos by AAV vectors.Scientific reports · 2024Article
- A knock-in allele of Hand2 expressing Dre recombinase.Genesis (New York, N.Y. : 2000) · 2024Article
- Review
- From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies.Biology · 2023Review
- Discovery and characterization of novel Cre-type tyrosine site-specific recombinases for advanced genome engineering.Nucleic acids research · 2023Article
- A novel lineage of osteoprogenitor cells with dual epithelial and mesenchymal properties govern maxillofacial bone homeostasis and regeneration after MSFL.Cell research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic technology using site-specific recombinases, such as the Cre-loxP system, has been widely employed for labeling specific cell populations and for studying their functions in vivo. To enhance the precision of cell lineage tracing and functional study, a similar site-specific recombinase system termed Dre-rox has been recently used in combination with Cre-loxP. To enable more specific cell lineage tracing and ablation through dual recombinase activity, we generated two mouse lines that render Dre- or Dre+Cre-mediated recombination to excise a stop codon sequence that prevents the expression of diphtheria toxin receptor (DTR) knocked into the ubiquitously expressed and safe Rosa26 locus. Using different Dre- and Cre-expressing mouse lines, we showed that the surrogate gene reporters tdTomato and DTR were simultaneously expressed in target cells and in their descendants, and we observed efficient ablation of tdTomato
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.